Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Aug 1;14(8):e0220178.
doi: 10.1371/journal.pone.0220178. eCollection 2019.

Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis

Benjamin Castagné  1   2 , Marie Viprey  2   3 , Julie Martin  2   3 , Anne-Marie Schott  2   3 , Michel Cucherat  4   5 , Martin Soubrier  1
Affiliations
Meta-Analysis

Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis

Benjamin Castagné et al. PLoS One. .

Abstract

Objectives: Our objective was to compare the cardiovascular safety of tocilizumab and other biological disease-modifying antirheumatic drugs (bDMARD) in rheumatoid arthritis using a network meta-analysis (NMA).

Methods: A systematic literature search through May 2018 identified randomized controlled trials (RCT) or observational studies (cohort only) reporting cardiovascular outcomes of tocilizumab (TCZ) and/or abatacept (ABA) and/or rituximab (RTX) and/or tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis patients. The composite primary outcome was the rate of major adverse cardiovascular outcomes (MACE, myocardial infarction (MI), peripheral artery disease (PAD) and cardiac heart failure (CHF)).

Results: 19 studies were included in the NMA, including 11 RCTs and 8 cohort studies. We found less events with RTX (5.41 [1.70;17.26]. We found no difference between TCZ and other treatments. Concerning MI, we found no difference between TCZ and csDMARD (4.23 [0.22;80.64]), no difference between TCZ and TNFi (2.00 [0.18;21.84]). There was no difference between TCZ and csDMARD (1.51[0.02;103.50] and between TCZ and TNFi (1.00 [0.06;15.85]) for stroke event. With cohorts and RCT NMA, we found no difference between TCZ and other treatments for MACE (0.66 [0.42;1.03] with ABA, 1.04 [0.60;1.81] with RTX, 0.78[0.53;1.16] and 0.91 [0.54;1.51] with csDMARD), but the risk of myocardial infarction was lower with TCZ compared to ABA (0.67 [0.47;0.97]). We lacked data to compare TCZ and other bDMARD for stoke and MI. Not enough data was available to perform a NMA for CHF and PAD.

Conclusions: Despite an increase in cholesterol levels, TCZ has safe cardiovascular outcomes compared to other bDMARD.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of the systematic literature review.
PubMed/Medline, Web of science, Cochrane library, Science direct and ACR, Annual College of Rheumatology; EULAR, European League Against Rheumatism databases.
Fig 2
Fig 2. NMA with RCT on major adverse cardiac events, myocardial infarction and stroke with TCZ vs other treatments.
comparison—Treatment comparison, k—Number of studies providing direct evidence, prop—Direct evidence proportion, nma—Estimated treatment effect (RR) in network meta-analysis, direct—Estimated treatment effect (RR) derived from direct evidence, indirect—Estimated treatment effect (RR) derived from indirect evidence, RoR—Ratio of Ratios (direct versus indirect), p-value—p-value of test for disagreement (direct versus indirect), TCZ—tocilizumab; csDMARDs—conventional synthetic disease-modifying antirheumatic drugs; TNFi—tumor necrosis factor inhibitor; ABA—abatacept; RTX—rituximab.
Fig 3
Fig 3. NMA with cohort studies on major adverse cardiac events, myocardial infarction and stroke with TCZ vs other treatments.
comparison—Treatment comparison, k—Number of studies providing direct evidence, prop—Direct evidence proportion, nma—Estimated treatment effect (RR) in network meta-analysis, direct—Estimated treatment effect (RR) derived from direct evidence, indirect—Estimated treatment effect (RR) derived from indirect evidence, RoR—Ratio of Ratios (direct versus indirect), p-value—p-value of test for disagreement (direct versus indirect), TCZ—tocilizumab; csDMARDs—conventional synthetic disease-modifying antirheumatic drugs; TNFi—tumor necrosis factor inhibitor; ABA—abatacept; RTX—rituximab.
Fig 4
Fig 4. NMA with both designs (RCT and cohorts) on major adverse cardiac events, myocardial infarction and stroke with TCZ vs other treatments.
comparison—Treatment comparison, k—Number of studies providing direct evidence, prop—Direct evidence proportion, nma—Estimated treatment effect (RR) in network meta-analysis, direct—Estimated treatment effect (RR) derived from direct evidence, indirect—Estimated treatment effect (RR) derived from indirect evidence, RoR—Ratio of Ratios (direct versus indirect), p-value—p-value of test for disagreement (direct versus indirect), TCZ—tocilizumab; csDMARDs—conventional synthetic disease-modifying antirheumatic drugs; TNFi—tumor necrosis factor inhibitor; ABA—abatacept; RTX—rituximab.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76: 960–977. 10.1136/annrheumdis-2016-210715 - DOI - PubMed
    1. Guillemin F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis. 2005;64: 1427–1430. 10.1136/ard.2004.029199 - DOI - PMC - PubMed
    1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59: 1690–1697. 10.1002/art.24092 - DOI - PubMed
    1. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74: 326–332. 10.1136/annrheumdis-2014-205675 - DOI - PMC - PubMed
    1. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70: 929–934. 10.1136/ard.2010.143396 - DOI - PubMed

Publication types

MeSH terms

Grants and funding

BC received financial support from the French society of rheumatology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.